Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Genmab A/S (GNMSF : OTC)

• Company Description    Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark. Number of Employees: 1,212

• Price / Volume Information    Yesterday's Closing Price: $288.08 Daily Weekly Monthly 20 Day Moving Average: 626 shares Shares Outstanding: 65.37 (millions) Market Capitalization: $18,831.79 (millions) Beta: 0.87 52 Week High: $500.92 52 Week Low: $274.93 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -25.37% -18.22% 12 Week -12.95% -5.54% Year To Date -26.23% -12.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL KALVEBOD BRYGGE 43 - COPENHAGEN,G7 1560 DNK ph: 45-7020-2728 fax: 45-7020-2729 acn@genmab.com http://www.genmab.com

• General Corporate Information    Officers Jan G. J. van de Winkel - President and Chief Executive Officer Anthony Mancini - Executive Vice President and Chief Operating Offic Anthony Pagano - Executive Vice President and Chief Financial Offic Judith Klimovsky - Executive Vice President Birgitte Stephensen - Senior Vice President Peer Information Genmab A/S (CORR.) Genmab A/S (RSPI) Genmab A/S (CGXP) Genmab A/S (BGEN) Genmab A/S (GTBP) Genmab A/S (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: K3967W102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/10/22 Share - Related Items Shares Outstanding: 65.37 Most Recent Split Date: (:1) Beta: 0.87 Market Capitalization: $18,831.79 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 51.35 PEG Ratio: - Price Ratios Price/Book: 5.50 Price/Cash Flow: 36.36 Price / Sales: 13.37 EPS Growth vs. Year Ago Period: -60.59% vs. Previous Quarter: -36.14% Sales Growth vs. Year Ago Period: 24.68% vs. Previous Quarter: -20.66% ROE 03/31/22 - 10.90 12/31/21 - 14.23 09/30/21 - 14.37 ROA 03/31/22 - 9.81 12/31/21 - 12.79 09/30/21 - 12.92 Current Ratio 03/31/22 - 17.31 12/31/21 - 14.50 09/30/21 - 12.00 Quick Ratio 03/31/22 - 17.31 12/31/21 - 14.50 09/30/21 - 12.00 Operating Margin 03/31/22 - 26.34 12/31/21 - 35.58 09/30/21 - 36.35 Net Margin 03/31/22 - 26.34 12/31/21 - 35.58 09/30/21 - 36.35 Pre-Tax Margin 03/31/22 - 35.16 12/31/21 - 46.96 09/30/21 - 46.67 Book Value 03/31/22 - 52.41 12/31/21 - 54.02 09/30/21 - 51.64 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©